ICER up­date on Duchenne drugs push­es up price es­ti­mates for Ex­ondys 51, Em­flaza ahead of Ju­ly pan­el re­view

In­creas­ing­ly in­flu­en­tial drug cost-ef­fec­tive­ness watch­dog ICER still doesn’t think that the drugs ap­proved to treat Duchenne mus­cu­lar dy­s­tro­phy have so far proved their val­ue to pa­tients. On Thurs­day, they used sig­nif­i­cant­ly high­er price es­ti­mates for two ther­a­pies in their mod­els, mak­ing them look even less at­trac­tive — and ac­knowl­edged that the es­ti­mates used in their draft re­port in May were in­cor­rect.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER